The Motley Fool

Is ‘vaping illness’ a sign British American Tobacco’s future is going up in smoke? 

Big Tobacco has had an incredible run. Its products were always addictive and easy to manufacture. Over time, as the health risks of smoking became undeniable, governments across the world opted to clamp down and tightly regulate the industry rather than ban the products altogether. 

The confluence of these factors made the tobacco industry one of the most concentrated and profitable industries on the planet. The aggregate profits for all major tobacco producers across the world exceeded US$62.27bn (£49.6bn) in 2015, the latest year with full records. 

Sign up for FREE issues of The Motley Fool Collective. Do you want straightforward views on what’s happening with the stock market, direct to your inbox? Help yourself with our FREE email newsletter designed to help you protect and grow your portfolio. Click here to get started now — it’s FREE!

In 2016, the five largest producers shipped 2.27tn cigarettes, which equates to more than 300 units for every human alive at the time. One of those large producers is London-based British American Tobacco (LSE:BATS), which reported £9.3bn in operating income last year.

Like other Big Tobacco leaders, BAT has managed to avoid death and taxes to create profits. A steady decline in the number of smokers in the developed world has been offset by a growing number of new smokers in emerging markets, particularly Asia. 

However, the industry understands that growth in the Asian market will eventually saturate like the rest of the world, which is why they have turned to a new source of potential growth – e-cigarettes, or vapes. 

These vaping products, or ‘new category’ products as BAT likes to call them, accounted for more than £1.8bn in sales last year. The company cut 2,300 staff earlier this year and has initiated a restructuring to focus on this segment and to double the sales of vaping-related items by 2024.  

Investors were so thrilled by the company injecting some fresh blood into its already lucrative business that they pushed the stock up by nearly a third earlier this year. 

However, I believe it’s too early for this sort of optimism. Not much is known about the long-term health consequences of vaping, and this year we started to see signs that this innovative new category may not be the panacea tobacco investors were hoping for. 

According to the Centers for Disease Control and Prevention (CDC), a new form of lung disease linked to the use of vaping products has already claimed eight lives and affected 530 people across the US. This week, Canada reported its first official case of vaping illness, when a teenager was put on life support. By Wednesday, the Indian government had announced a blanket ban on all vaping products across the country.

I wouldn’t be surprised if more cases and more bans emerged in the years ahead. Governments may be compelled to step in and nip this issue in the bud. That could mean BAT’s hopes of growth could be going up in smoke.

Nonetheless, BAT is far from being a doomed company or a bad investment, in my opinion. As I mentioned in my previous article, more than a billion people are still addicted to tobacco and could help cover the 7% dividend yield BAT currently offers, for decades to come. 

Foolish takeaway

I believe BAT is still an excellent dividend stock for income-seeking investors. However, concerns about the health risks of e-cigarettes could be denting the company’s growth story.

A Growth Gem

Research into unloved sectors can often unearth fantastic growth opportunities to help boost your wealth – and one of Fool UK’s contributors believes they’ve identified one such winner, which could be a bona-fide bargain at recent levels!

To find out the name of this company, and to get the full research report absolutely free of charge, click here now.

VisheshR has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.